Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБУ «3 ЦВКГ им. А.А.Вишневского» МО РФ 143420 Московская обл., Красногорский р-н, п/о Архангельское, пос. Новый 2Российский университет дружбы народов кафедра госпитальной хирургии с курсом детской хирургии 111000 Россия, г. Москва, ул. Миклухо-Маклая, 8
Long-term outcomes of endovascular interventions in patients with return of angina after coronary bypass
Список исп. литературыСкрыть список 1. Goldman S., Zadina K., Moritz T., et al. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. J. Am. Coll. Cardiol. 2004; 44:2149 –56. 2. Бокерия Л.А., Алекян Б.Г. Руководство по рентгеноэндоваскулярной хирургии сердца и сосудов. Москва. Издательство НЦССХ им. А.Н. Бакулева РАМН. 2008. том 3; 592с. Bokerija L.A., Alekjan B.G. Rukovodstvo po rentgenojendovaskuljarnoj hirurgii serdca i sosudov [Guideline for endovascular surgery of vesels and heart]. Moskva. Izdatel'stvo NCSSH im. A.N. Bakuleva RAMN. 2008. tom 3; 592s [In Russ]. 3. Brilakis E.S., de Lemos J.A., Cannon C.P., et al. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). Am.J. Cardiol. 2008;102:552–8. 4. Brilakis E.S., Wang T.Y., Rao S.V., et al. Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry. JACC Cardiovasc Interv. 2010; 3:1068-73. 5. Brodie B.R., Wilson H., Stuckey T., et al. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group. JACC Cardiovasc Interv. 2009; 2:1105–12. 6. Brilakis E.S1, Rao S.V., Banerjee S., et al. Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2011 Aug;4(8): 844–50. 7. Michael T.T., Karmpaliotis D., Brilakis E.S., et al. Impact of prior coronary artery bypass graft surgery on chronic total occlusion revascularisation: insights from a multicentre US registry. Heart. 2013; 99(20):15151518. 8. Brodie B.R., Versteeg D.S., Brodie M.M., et al. Poor long-term patient and graft survival after primary percutaneous coronary intervention for acute myocardial infarction due to saphenous vein graft occlusion. Catheter Cardiovasc. Interv. 2005; 65:504–9. 9. Babunashvili A. M. Ivanov V. A.: Hronicheskie okkljuzii koronarnyh arterij: anatomija, patofiziologija, jendovaskuljarnoe lechenie: Monografija. Moskva: Izdatel'stvo ACB. 2012; 487–509 [In Russ]. 10. Jeroudi OM, Alomar ME, Michael TT, et al. Prevalence and management of coronary chronic total occlusions in a tertiary veterans affairs hospital. J. Am. Coll. Cardiol. 2013; 62(18_S1):B113–B113. 11. Rolf A., Werner G.S., Schuhback A., et al. Preprocedural coronary CT angiography significantly improves success rates of PCI for chronic total occlusion. Int. J. Cardiovasc Imaging. 2013; 29(8):18191827. 12. Hakeem A., Helmy T., Munsif S., et al. Safety and efficacy of drug eluting stents compared with bare metal stents for saphenous vein graft interventions: a comprehensive meta-analysis of randomized trials and observational studies comprising 7,994 patients. Catheter Cardiovasc. Interv. 2011; 77:343–55. 13. Lee M.S., Yang T., Kandzari D.E., et al. Comparison by metaanalysis of drug-eluting stents and bare metal stents for saphenous vein graft intervention. Am. J. Cardiol. 2010;105:1076-82. 14. Rodés-Cabau J., Bertrand O.F., Larose E., et al. Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment of moderate non-significant saphenous vein graft lesions: the moderate vein graft lesion stenting with the taxus stent and intravascular ultrasound (VELETI) pilot trial. Circulation. 2009; 120(20): 1978–1986. 15. Testa L., Agostoni P., Vermeersch P., et al. Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis. EuroIntervention 2010;6:527–36. 16. Wiisanen M.E., bdel-Latif A., Mukherjee D., et al. Drug-eluting stents versus bare-metal stents in saphenous vein graft interventions: a systematic review and meta-analysis. JACC Cardiovasc. Interv. 2010; 3:1262–73. 17. Ijsselmuiden A.J.J., Ezechiels J.P., Westendorp I.C.D. et al. Complete versus culprit vessel percutaneous coronary intervention in multivessel disease: A randomized comparison. Am. Heart J. 2004; 148: 467–474. 18. Sarno G., Garg S., Onuma Y. et al. Impact of completeness of revascularization on the five-year outcome in percutaneous coronary intervention and coronary artery bypass graft patients (from the ARTS-II study). Am. J. Card. 2010; 106: 1369–1375. 19. Ijsselmuiden A.J.J., Ezechiels J.P., Westendorp I.C.D. et al. Complete versus culprit vessel percutaneous coronary intervention in multivessel disease: A randomized comparison. Am. Heart J. 2004; 148: 467–474. 20. Sarno G., Garg S., Onuma Y. et al. Impact of completeness of revascularization on the five-year outcome in percutaneous coronary intervention and coronary artery bypass graft patients (from the ARTS-II study). Am. J. Card. 2010; 106: 1369–1375. 21. Brilakis E.S., Lichtenwalter C., de Lemos J.A., et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J. Am. Coll. Cardiol. 2009; 53:919–28. 22. Brilakis E.S., Papayannis A.C., Abdel-Karim A.R., et al. TCT abstract 219: prospective evalation of the Xience V everolimus-eluting stent in saphenous vein graft atherosclerosis: the Xience V-SVG Angiographic Study. J. Am. Coll. Cardiol. 2011; 58:B59. 23. Harskamp R.E., Lopes R.D., Baisden C.E., de Winter R.J., Alexander JH. Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions. Ann. Surg. 2013;257(5): 824–833. 24. Kitabata H., Loh J.P., Pendyala L.K., et al. Two-year follow-up of outcomes of second-generation everolimus-eluting stents versus first-generation drug-eluting stents for stenosis of saphenous vein grafts used as aortocoronary conduits. Am. J. Cardiol. 2013; 112(1):61–67. 25. Mehilli J., Pache J., Abdel-Wahab M., et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet. 2011; 378:1071–8. 26. Serruys P.W., Onuma Y., Garg S. et al. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J. Am. Coll. Cardiol. 2010 Mar 16; 55(11):1093-101. 27. Shah S.J., Waters D.D., Barter P., et al. Intensive lipid-lowering with atorvastatin for secondaryprevention in patients after coronary artery bypass surgery. J. Am. Coll. Cardiol. 2008; 51:1938–43. 28. Zhou Q., Liao J.K.. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr. Pharm. Des 2009; 15:467–78. 29. Iakovou I., Schmidt T., Bonizzoni E. et al. Incidence, predictors and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293: 2126–2130. 30. Al-Lamee R., Ielasi A., Latib A., et al. Clinical and angiographic outcomes after percutaneous recanalization of chronic total saphenous vein graft occlusion using modern techniques. Am. J. Cardiol. 2010;106(12):1721–1727. 31. Hougaard M., Thayssen P., Kaltoft A., et al. Long-term outcome following percutaneous coronary intervention with drug-eluting stents compared with bare-metal stents in saphenous vein graft lesions: from Western Denmark heart registry. Catheter. Cardiovasc. Interv. 2014; 83(7):1035–1042. 32. Meliga E., García-García H.M., Kukreja N., et al. Chronic total occlusion treatment in post-CABG patients: saphenous vein graft versus native vessel recanalization — long-term follow-up in the drug-eluting stent era. Catheter Cardiovasc Interv. 2007; 70(1):21-25. 33. Ybarra L.F., Ribeiro H.B., Pozetti A.H., et al. Long-term follow-up of drug eluting versus bare metal stents in the treatment of saphenous vein graft lesions. Catheter Cardiovasc Interv. 2013;82(7):E856-E863. 34. Hannan E.L., Racz M., Holmes D.R. et al. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation 2006; 113: 2406–2412. 35. Hannan E.L., Wu C., Walford G. et al. Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes. J. Am. Coll. Cardiol. Intv. 2009; 2: 17–25. 36. Rodriguez A.E., Maree A.O., Grinfeld L. et al. Revascularization strategies of coronary multiple vessel disease in drug eluting stent era: one year follow-up results of ERACI III trial. Eurointervention. 2006; 2: 53–60. 37. Rodriguez A.E., Maree A.O., Mieres J. et al. Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. Eur. Heart J. 2007; 28: 2118–2125. 38. Kukreja N., Serruys P.W., de Bruyne B. et al. Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II). Heart 2009; 95(13): 1061–1066. 39. Serruys P.W., Donohoe D.J., Wittebols K. et al. The clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularization Therapies Study part II (ARTS II). Eur. Heart J. 2007; 28(4): 433–442. 40. Serruys P.W., Stoll H.P., Macours N. et al. Multivessel coronary revascularization in patients with and without diabetes mellitus 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial. J. Am. Coll. Cardiol. 2008; 52(24): 1957–1967. 41. Fajadet J., Wijns W., Laarman G.J. et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006; 114: 798–806. 42. Hodgson J.M.B., Stone G.W., Lincoff A.M. et al. Late stent trombosis: considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force. Cathet. Cardiovasc. Interv. 2007; 69: 135–142. 43. Lasala J.M., Cox D.A., Morris D.L. et al. Two-year results of paclitaxel-eluting stent in patients with medically treated diabetes mellitus from the TAXUS ARRIVE program. Am. J. Card. 2009; 103(12): 1663–1671. 44. Lotan C., Meredith I.T., Mauri L. et al. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry. J. Am. Coll. Cardiol. Intv. 2009; 2: 1227–1235. 45. Stone G.W., Ellis S.G., O’Shaughnessy C.D. et al. Paclitaxel-eluting stents vs. vascular brachytherapy for in stent restenosis within bare-metal stents. JAMA. 2006; 295: 1253–1263.